DEXA | Jotup

Solarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone Loss

Retrieved on:

Mittwoch, Mai 8, 2024

Mortality, Inflammation, Cell, Woman, Osteoclast, Health, GRAS, Partnership, Doctor of Philosophy, DEXA, Osteoporosis, Physician, BMD, Peri, Fruit, Quality of life, Menopause, Dietary supplement

BOSTON, May 8, 2024 /PRNewswire/ -- All peri- and postmenopausal women experience bone loss, which can lead to osteoporosis if left unmanaged. And although osteoporosis is exceedingly common, afflicting 1 in 3 women, most are unaware of their condition and the implications that it can have for their health. An osteoporotic injury can be devastating, significantly reducing quality of life and—in the worst cases—resulting in a 30% mortality rate in the first-year post-hip fracture.

Key Points:

BOSTON, May 8, 2024 /PRNewswire/ -- All peri- and postmenopausal women experience bone loss, which can lead to osteoporosis if left unmanaged.
Initially debuting via a private beta program, their first-ever product, Bondia™ medical food, is a daily synbiotic capsule that helps address bone loss in peri- and postmenopausal women.
Bondia™ medical food is Journa's naturally developed, clinical solution to manage postmenopausal bone loss.
In preparation for its private beta program, Bondia™ medical food is currently undergoing a double-blind, placebo-controlled clinical food trial in 286 early postmenopausal women.

Seed Health Launches Computational Biology Platform, Powered by Most Comprehensive Host-Microbiome Data Set, to Expand Pipeline Beyond the Gut

Retrieved on:

Donnerstag, April 11, 2024

BOSTON, April 11, 2024 /PRNewswire/ -- Seed Health today launched CODA, a computational biology platform for the discovery and development of next-generation precision probiotics and microbiome-directed interventions. The platform is powered by the Human Phenotype Project—the world's most comprehensive multi-omics data set, emerging from the lab of computational biologist Professor Eran Segal, Ph.D., at the Weizmann Institute of Science. CODA elucidates previously unknown connections between the microbiome and health to develop targeted, outcome-specific interventions. First programs include cardiometabolic health, brain health, menopause, and longevity.

Key Points:

"Our CODA platform is tracking the health data of tens of thousands of individuals over decades, offering a comprehensive, multi-omics perspective," explained Raja Dhir, Co-Founder of Seed Health.
Such insights reveal a clear distinction between biological and chronological age, offering a more comprehensive understanding of health and disease patterns.
This comprehensive approach allows us to unravel the complex interactions between diet, supplementation, the microbiome, and multi-system human health more effectively than before."
"CODA significantly expands our platform's capacity to realize the full promise of the microbiome," said Ara Katz, Co-CEO and Co-Founder of Seed Health.

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Retrieved on:

Donnerstag, April 11, 2024

Furthermore LPCN 2401 could help to attenuate collateral fattening and rebound fat/weight "overshoot" associated with discontinuation of GLP-1/GIP agonists.

Key Points:

Furthermore LPCN 2401 could help to attenuate collateral fattening and rebound fat/weight "overshoot" associated with discontinuation of GLP-1/GIP agonists.
We look forward to meeting with the FDA to discuss the further development of LPCN 2401 as an aid to weight management interventions."
Analyses of body composition parameters, including prespecified endpoints of whole body LM and whole-body FM, are reported in the table below.
An overall improvement in body composition is evidenced by substantial decrease in the fat mass to lean mass ratio.

Aurora Spine Corporation Celebrates Second Anniversary of Initial Implantation of the World’s First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Retrieved on:

Mittwoch, März 20, 2024

ASG, ACDF, Institutional review board, MRI, Patent, Patient, United, Degenerative disc disease, DEXA, DDD, Neurosurgery, Bone density, Spine, Trial of the century, IRB

The DEXA-C implants, a line of cervical cages for anterior cervical discectomy with fusion (ACDF) procedures, are the first of its kind in the world offering an implant based upon a patient's bone density.

Key Points:

The DEXA-C implants, a line of cervical cages for anterior cervical discectomy with fusion (ACDF) procedures, are the first of its kind in the world offering an implant based upon a patient's bone density.
I am able to confidently offer multilevel anterior fusions to patients who likely could not have benefitted from other existing implants because of their bone density.
In June 2023, Aurora announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System.
Preliminarily, we have seen both in radiographs and surgical exploration that patients have incipient bone fusion by 90 days after surgery.

RadNet and JVS SoCal Create ImagingWorks®, an Innovative Partnership to Launch Career Training Programs for Medical Imaging

Retrieved on:

Donnerstag, Februar 15, 2024

Student, Tech, Social responsibility, Dignity, RadNet, JVS, Health, Dual-energy X-ray absorptiometry, Employment, Accreditation, Google Images, Insurance, PSR, MRI, DEXA, Partnership, Nursing

(RadNet’s President and Chief Executive Officer), are helping close the opportunity gap in a specialized field that equips students for well-paying, meaningful careers in medical imaging.

Key Points:

(RadNet’s President and Chief Executive Officer), are helping close the opportunity gap in a specialized field that equips students for well-paying, meaningful careers in medical imaging.
We are proud to partner with Karen and Howard Berger and RadNet on this special initiative,” said JVS SoCal CEO Jeff Carr.
“RadNet has been a leading employer-partner of JVS SoCal, especially in our CareerWork$ Medical® program, having hired dozens of graduates since 2019.
Through the new ImagingWorks® partnership, RadNet continues its legacy of community involvement and social responsibility,” concluded Mr. Carr.

Aurora Spine’s Second Patent Related to DEXA Technology™ Patient-Matched Implant Technology Issued by the United States Patent Office

Retrieved on:

Montag, Februar 5, 2024

ASG, Osteoporosis, Surgeon, Patent, Science, United, Bone density, Ageing, Patient, Orthopedic surgery, Physician, DEXA, Dentistry

Aurora Spine’s first-of-its kind DEXA Technology™ is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support.

Key Points:

Aurora Spine’s first-of-its kind DEXA Technology™ is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support.
Aurora Spine’s DEXA Technology™ is part of the company's advanced portfolio representing the future of Spinal and Orthopedic implants.
Following fundamental principles of patent focused innovation, DEXA Technology™ was logically created and patented to combine the essential design benefits of conventional machining and additive implant manufacturing.
The proprietary engineering behind our DEXA Technology™ is advancing the science of implant technology, and ultimately helping improve patient fusion rates and overall clinical outcomes.

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on:

Dienstag, November 28, 2023

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points:

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
“We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
“Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi

Retrieved on:

Mittwoch, Oktober 4, 2023

MIAMI, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, breast cancer and for viral induced ARDS, today announced that the Company will advance its proprietary novel agent, enobosarm, a selective androgen receptor modulator (SARM), into a Phase 2b clinical trial in combination with weight-loss GLP-1 drugs, Ozempic (semaglutide), Wegovy (semaglutide), or Mounjaro (tirzepatide) to evaluate the efficacy and the safety of enobosarm to further increase fat loss while preventing the significant muscle wasting that occurs with weight-loss GLP-1 drugs.

Key Points:

Specifically, enobosarm therapy could augment the preferential loss of fat mass while preventing the loss of critical muscle mass and bone mineral density.
Enobosarm treatment could also preserve or improve muscle strength and physical function in older adults being treated with a weight loss drug.
The primary endpoint of the study will be change in total lean body mass (muscle) from baseline to 4 months.
Key secondary endpoints will be change from baseline to 4 months in total fat mass, insulin resistance (HOMA-IR), and body weight.

Studies Show GLP-1 Weight-Loss Drugs Leading to Loss of Critical Lean Mass

Retrieved on:

Montag, Oktober 2, 2023

Composition, Weight loss, Patient, STEP, DEXA, Health, Failure, Body composition, Risk, Dietary supplement, Medical imaging

AUSTIN, Texas, Oct. 2, 2023 /PRNewswire/ -- BodySpec, the leader in advanced mobile body composition scans, warns that a significant proportion of the weight loss seen with GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, may be lean tissue. While these drugs have been praised for their ability to help people drop weight quickly, it is important to understand the potential risks associated with this rapid weight loss and the ways to mitigate risks with regular body composition scans during treatment.

Key Points:

Recent studies show up to 40% of mass lost during GLP-1 treatment was lean mass, leading to unintended consequences.
In another study of 178 patients from the SUSTAIN 8 trial on semaglutide, the average proportion of lean mass loss was nearly identical at 40% (1).
Additionally, losing lean mass can make it more difficult to maintain weight loss over the long term (2).
It is critical to monitor body composition with a DEXA scan to ensure that patients are not being set up for failure by losing lean mass.

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Retrieved on:

Dienstag, September 26, 2023

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Key Points:

For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.
Exploratory biomarker data were collected throughout the study to provide evidence of the potential for disease modification with ongoing treatment with INZ-701.
For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
PK properties were consistent with those observed in the Phase 1/2 clinical trial in adults with ENPP1 Deficiency.